Cargando…
A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol
BACKGROUND: For people with advanced-stage Kaposi’s sarcoma (KS), a common HIV-associated malignancy in sub-Saharan Africa, mortality is estimated to be 45% within 2 years after KS diagnosis, despite increasingly wide-spread availability of antiretroviral therapy and chemotherapy. For advanced-stage...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102240/ https://www.ncbi.nlm.nih.gov/pubmed/35562783 http://dx.doi.org/10.1186/s43058-022-00281-7 |
_version_ | 1784707282516312064 |
---|---|
author | Collier, Sigrid Semeere, Aggrey Byakwaga, Helen Laker-Oketta, Miriam Chemtai, Linda Wagner, Anjuli D. Bassett, Ingrid V. Wools-Kaloustian, Kara Maurer, Toby Martin, Jeffrey Kiprono, Samson Freeman, Esther E. |
author_facet | Collier, Sigrid Semeere, Aggrey Byakwaga, Helen Laker-Oketta, Miriam Chemtai, Linda Wagner, Anjuli D. Bassett, Ingrid V. Wools-Kaloustian, Kara Maurer, Toby Martin, Jeffrey Kiprono, Samson Freeman, Esther E. |
author_sort | Collier, Sigrid |
collection | PubMed |
description | BACKGROUND: For people with advanced-stage Kaposi’s sarcoma (KS), a common HIV-associated malignancy in sub-Saharan Africa, mortality is estimated to be 45% within 2 years after KS diagnosis, despite increasingly wide-spread availability of antiretroviral therapy and chemotherapy. For advanced-stage KS, chemotherapy in addition to antiretroviral therapy improves outcomes and saves lives, but currently, only ~50% of people with KS in western Kenya who have an indication for chemotherapy actually receive it. This protocol describes the evaluation of a multicomponent patient navigation strategy that addresses common barriers to service penetration of and fidelity to evidence-based chemotherapy among people with advanced-stage KS in Kenya. METHODS: This is a hybrid type III effectiveness-implementation study using a non-randomized, pre- post-design nested within a longitudinal cohort. We will compare the delivery of evidence-based chemotherapy for advanced-stage KS during the period before (2016–2020) to the period after (2021–2024), the rollout of a multicomponent patient navigation strategy. The multicomponent patient navigation strategy was developed in a systematic process to address key determinants of service penetration of and fidelity to chemotherapy in western Kenya and includes (1) physical navigation and care coordination, (2) video-based education, (3) travel stipend, (4) health insurance enrollment assistance, (5) health insurance stipend, and (6) peer mentorship. We will compare the pre-navigation period to the post-navigation period to assess the impact of this multicomponent patient navigation strategy on (1) implementation outcomes: service penetration (chemotherapy initiation) and fidelity (chemotherapy completion) and (2) service and client outcomes: timeliness of cancer care, mortality, quality of life, stigma, and social support. We will also describe the implementation process and the determinants of implementation success for the multicomponent patient navigation strategy. DISCUSSION: This study addresses an urgent need for effective implementation strategies to improve the initiation and completion of evidence-based chemotherapy in advanced-stage KS. By using a clearly specified, theory-based implementation strategy and validated frameworks, this study will contribute to a more comprehensive understanding of how to improve cancer treatment in advanced-stage KS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43058-022-00281-7. |
format | Online Article Text |
id | pubmed-9102240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91022402022-05-14 A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol Collier, Sigrid Semeere, Aggrey Byakwaga, Helen Laker-Oketta, Miriam Chemtai, Linda Wagner, Anjuli D. Bassett, Ingrid V. Wools-Kaloustian, Kara Maurer, Toby Martin, Jeffrey Kiprono, Samson Freeman, Esther E. Implement Sci Commun Study Protocol BACKGROUND: For people with advanced-stage Kaposi’s sarcoma (KS), a common HIV-associated malignancy in sub-Saharan Africa, mortality is estimated to be 45% within 2 years after KS diagnosis, despite increasingly wide-spread availability of antiretroviral therapy and chemotherapy. For advanced-stage KS, chemotherapy in addition to antiretroviral therapy improves outcomes and saves lives, but currently, only ~50% of people with KS in western Kenya who have an indication for chemotherapy actually receive it. This protocol describes the evaluation of a multicomponent patient navigation strategy that addresses common barriers to service penetration of and fidelity to evidence-based chemotherapy among people with advanced-stage KS in Kenya. METHODS: This is a hybrid type III effectiveness-implementation study using a non-randomized, pre- post-design nested within a longitudinal cohort. We will compare the delivery of evidence-based chemotherapy for advanced-stage KS during the period before (2016–2020) to the period after (2021–2024), the rollout of a multicomponent patient navigation strategy. The multicomponent patient navigation strategy was developed in a systematic process to address key determinants of service penetration of and fidelity to chemotherapy in western Kenya and includes (1) physical navigation and care coordination, (2) video-based education, (3) travel stipend, (4) health insurance enrollment assistance, (5) health insurance stipend, and (6) peer mentorship. We will compare the pre-navigation period to the post-navigation period to assess the impact of this multicomponent patient navigation strategy on (1) implementation outcomes: service penetration (chemotherapy initiation) and fidelity (chemotherapy completion) and (2) service and client outcomes: timeliness of cancer care, mortality, quality of life, stigma, and social support. We will also describe the implementation process and the determinants of implementation success for the multicomponent patient navigation strategy. DISCUSSION: This study addresses an urgent need for effective implementation strategies to improve the initiation and completion of evidence-based chemotherapy in advanced-stage KS. By using a clearly specified, theory-based implementation strategy and validated frameworks, this study will contribute to a more comprehensive understanding of how to improve cancer treatment in advanced-stage KS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43058-022-00281-7. BioMed Central 2022-05-13 /pmc/articles/PMC9102240/ /pubmed/35562783 http://dx.doi.org/10.1186/s43058-022-00281-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Collier, Sigrid Semeere, Aggrey Byakwaga, Helen Laker-Oketta, Miriam Chemtai, Linda Wagner, Anjuli D. Bassett, Ingrid V. Wools-Kaloustian, Kara Maurer, Toby Martin, Jeffrey Kiprono, Samson Freeman, Esther E. A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol |
title | A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol |
title_full | A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol |
title_fullStr | A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol |
title_full_unstemmed | A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol |
title_short | A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol |
title_sort | type iii effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage kaposi’s sarcoma: protocol |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102240/ https://www.ncbi.nlm.nih.gov/pubmed/35562783 http://dx.doi.org/10.1186/s43058-022-00281-7 |
work_keys_str_mv | AT colliersigrid atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT semeereaggrey atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT byakwagahelen atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT lakerokettamiriam atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT chemtailinda atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT wagneranjulid atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT bassettingridv atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT woolskaloustiankara atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT maurertoby atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT martinjeffrey atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT kipronosamson atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT freemanesthere atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT colliersigrid typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT semeereaggrey typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT byakwagahelen typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT lakerokettamiriam typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT chemtailinda typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT wagneranjulid typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT bassettingridv typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT woolskaloustiankara typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT maurertoby typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT martinjeffrey typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT kipronosamson typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol AT freemanesthere typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol |